Propulsid Articles
Banned drugs "sold freely" in India
23 July 2007
US Senate views J&J's Propulsid promo
18 July 2005
Israel studies worldwide politics of pharmaceutical reimbursement
23 February 2004
Kyowa Hakko lowers earnings forecasts
8 April 2002
Stock Commentary - New York
6 December 2001
Pharma sales down at Kyowa Hakko
28 November 2001
India looking at WHO-banned drugs
19 October 2001
J&J to fight $100 mill Propulsid award
4 October 2001
Stock Commentary - Tokyo
19 July 2001
Japan pharma stocks - week to July 16
18 July 2001
J&J, Health Canada sued over drug death
13 July 2001
Health Canada to act on "slow" drug alerts
16 May 2001
J&J beats forecasts with 14% EPS rise
18 April 2001
Italian Propulsid warnings "ineffective"
17 April 2001
Stock Commentary - Tokyo
8 March 2001
Tokyo stock watch, week to March 5
7 March 2001
Stock Commentary - Tokyo
15 February 2001
J&J sales up despite Propulsid problem
24 January 2001
Stock Commentary - Tokyo
14 December 2000
Stock Commentary - Tokyo
23 November 2000
Johnson & Johnson earnings climb 14%
18 October 2000
MCA withdraws J&J Prepulsid license
21 July 2000
J&J beats forecasts with 2nd qtr earnings
20 July 2000
Stock Commentary Tokyo
11 May 2000
Stock Commentary Tokyo
4 May 2000
Stock Commentary Tokyo
27 April 2000
Johnson & Johnson net earnings rise 15.5%
19 April 2000
Stock Commentary New York
6 April 2000
Stock Commentary Europe
3 April 2000
Stock Commentary Tokyo
3 April 2000
Stock Commentary New York
3 April 2000
Concern over warning labels' effectiveness
27 March 2000
AstraZeneca's Effect On Rest Of Pharma Sector
17 December 1998
Lilly Licenses Prozac Successor
8 December 1998
ICAgen To Start Trials Of Three Drugs In 1999
25 November 1998
Mosapride Launched
15 October 1998
Sepracor To Develop Improved Propulsid
23 July 1998
Stock Commentary New York
9 July 1998
Warnings To Be Added To US Propulsid Labeling
1 July 1998
J&J 1st Quarter Earnings Rise But Strong $ Hits Sales
15 April 1998
Highlights Of Astra's Pipeline Presentation
30 January 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
J&J 3rd Qtr Earnings Rise But Sales Hit By Strong $
16 October 1997
Positive Verdict On Roche's Posicor From FDA Panel
10 March 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
Zocor "Will Be World's Top-Selling Drug In 2005"
13 January 1997
USA Approves Sporanox Pulse Dosing
23 December 1996
Dutch Government Reimbursement Blacklist Rises To 35
9 December 1996
Major US Drug Cos Post Strong Results In 3rd Qtr
28 October 1996
Accolate Cleared In USA For Asthma; 1st In Class
7 October 1996
Yoshitomi Products See Sales Growth
24 June 1996
US Firms' Strong 1st Qtr Lifts Share Prices
29 April 1996
Transition For AHP in 1995; Year-End Results
5 February 1996
Astra Strengthens R&D With Increased Spending
4 December 1995
Mixed Interims From Japanese Drug Majors
20 November 1995
Belmac/Technimede cisapride deal
21 August 1995
Strong International Sales For US Cos In 2nd Qtr
31 July 1995
Japan's Drugmakers Post Mixed End Year Results
26 June 1995
Weaker US Dollar And Volume Growth Lift 1st Qtr
24 April 1995
Labelling Change For Cisapride
20 March 1995
Janssen-Cilag Issues Dear Doctor
13 March 1995
End Of Year Encouraging For US Companies
6 February 1995
Solid 3rd Qtr Growth For Large Pharma Cos
31 October 1994
France Cuts Drug Prices, Bans Promo Campaigns
5 September 1994
Strong Gains By US Firms In 2nd Quarter
1 August 1994
DAINIPPON LICENSES MOSAPRIDE TO ASTRA
28 February 1994
RESTRUCTURING CHARGES DEPRESS LILLY AND E KODAK
14 February 1994
JAPANESE FIRST-HALF RESULTS AND FORECASTS
6 December 1993
US 3rd QTR AFFECTED BY STRONG DOLLAR
1 November 1993
PROPULSID APPROVED FOR NIGHT HEARTBURN
9 August 1993
NICOTINE PATCH COs SUFFER DECLINE IN US SALES
2 August 1993
GASTROENTEROLOGY CONFERENCE REPORT
26 July 1993
STRONG GROWTH BY US PHARMA COs IN 1st QTR
10 May 1993
PROPULSID APPROVAL IN THE USA
26 April 1993
US 4th QTR SHOWS NOT ALL COMPANIES STRONG
15 February 1993
LONG-TERM USE OF CISAPRIDE IN UK
18 January 1993
US RESULTS 3RD QTR
2 November 1992
JANSSEN TO MARKET ALIMIX IN UK
6 July 1992
JANSSEN'S PREPULSID: NEW FORM IN UK
8 June 1992
H PYLORI TREATMENT: A ROLE FOR OMEPRAZOLE?
25 May 1992
GOOD 1st QTRs for ALZA, IMMUNEX AND MYLAN
4 May 1992
US PANEL CALLS FOR PROPULSID APPROVAL
4 May 1992
JANSSEN'S CISAPRIDE IN USA
20 April 1992
Showing 1-98 of 98 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
